Reports Q2 revenue $136.1M, consensus $130.26M. “Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio, particularly in our AtriClip platform and cryoSPHERE device offerings. We’re seeing increasing momentum as our new technologies drive deeper adoption, reduced procedure times, and improved patient outcomes,” said Michael Carrel, President and Chief Executive Officer at AtriCure (ATRC). “With this foundation, we’re excited about the opportunities ahead in the second half of 2025 and beyond to continue delivering strong growth and expanding profitability.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC: